Trials / Completed
CompletedNCT00909740
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, first-in-human, open-label, dose-escalation study of MEGF0444A administered by IV infusion to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEGF0444A | Intravenous escalating dose |
Timeline
- Start date
- 2009-05-22
- Primary completion
- 2011-10-26
- Completion
- 2011-10-26
- First posted
- 2009-05-28
- Last updated
- 2022-12-12
Source: ClinicalTrials.gov record NCT00909740. Inclusion in this directory is not an endorsement.